CA2402268A1 - Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections - Google Patents
Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections Download PDFInfo
- Publication number
- CA2402268A1 CA2402268A1 CA002402268A CA2402268A CA2402268A1 CA 2402268 A1 CA2402268 A1 CA 2402268A1 CA 002402268 A CA002402268 A CA 002402268A CA 2402268 A CA2402268 A CA 2402268A CA 2402268 A1 CA2402268 A1 CA 2402268A1
- Authority
- CA
- Canada
- Prior art keywords
- sequence
- rsv
- iss
- purine
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Abstract
The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV), particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being exposed to a respiratory virus, has been exposed to a respiratory virus or is infected with a respiratory virus. The ISS is administered without any antigens of the respiratory virus. Administration of the ISS results in reduced incidence and/or severity of one or more symptoms of respiratory virus infection.
Claims (15)
1. A method of suppressing a respiratory syncytial virus (RSV) infection in an individual who has been exposed to RSV, comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5'-C, G-3', wherein an RSV
antigen is not administered in conjunction with administration of said composition, and wherein said composition is administered in an amount sufficient to suppress a RSV
infection.
antigen is not administered in conjunction with administration of said composition, and wherein said composition is administered in an amount sufficient to suppress a RSV
infection.
2. The method of claim 1, wherein the ISS comprises the sequence 5'-T, C, G-
3'.
3. The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.
3. The method of claim 1, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3'.
4. The method of claim 3, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3', and 5'-GACGTTCG-3' .
5. The method of claim 1, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).
6. The method of claim 1, wherein the individual is a mammal.
7. The method of claim 1, wherein administration is at a site of exposure.
8. The method of claim 7, wherein the site of exposure is respiratory mucosa.
9. The method of claim 7, wherein the site of exposure is the nasal passages.
10. The method of claim 1, wherein the suppression comprises a reduction of RSV
titer in a biological sample from said individual.
titer in a biological sample from said individual.
11. A kit for use in suppressing a respiratory syncytial virus (RSV) infection in an individual infected with or exposed to RSV, comprising:
a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-C, G-3' and wherein said kit does not comprises an RSV antigen; and instructions for administration of said composition to an individual infected with or exposed to RSV to suppress RSV infection.
a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5'-C, G-3' and wherein said kit does not comprises an RSV antigen; and instructions for administration of said composition to an individual infected with or exposed to RSV to suppress RSV infection.
12. The kit of claim 11, wherein the ISS comprises the sequence 5'-T, C, G-3'.
13. The kit of claim 11, wherein the ISS comprises the sequence 5'-purine, purine, C, G, pyrimidine, pyrimidine, G, G-3' or 5'-purine, purine, C, G, pyrimidine, pyrimidine, C, C-3' .
14. The kit of claim 13, wherein the ISS comprises a sequence selected from the group consisting of 5'-AACGTTCC-3', 5'-AACGTTCG-3', 5'-GACGTTCC-3' and 5'-GACGTTCG-3' .
15. The kit of claim 11, wherein the ISS comprises the sequence 5'-TGACTGTGAACGTTCGAGATGA-3' (SEQ ID NO:1).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18858300P | 2000-03-10 | 2000-03-10 | |
US60/188,583 | 2000-03-10 | ||
US09/802,686 | 2001-03-09 | ||
US09/802,686 US20010046967A1 (en) | 2000-03-10 | 2001-03-09 | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
PCT/US2001/007839 WO2001068116A2 (en) | 2000-03-10 | 2001-03-12 | Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2402268A1 true CA2402268A1 (en) | 2001-09-20 |
CA2402268C CA2402268C (en) | 2012-10-02 |
Family
ID=26884244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2402268A Expired - Fee Related CA2402268C (en) | 2000-03-10 | 2001-03-12 | Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections |
Country Status (8)
Country | Link |
---|---|
US (3) | US20010046967A1 (en) |
EP (1) | EP1261352B1 (en) |
JP (1) | JP2003526672A (en) |
AT (1) | ATE476983T1 (en) |
AU (2) | AU4358701A (en) |
CA (1) | CA2402268C (en) |
DE (1) | DE60142775D1 (en) |
WO (1) | WO2001068116A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727230B1 (en) * | 1994-03-25 | 2004-04-27 | Coley Pharmaceutical Group, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US7935675B1 (en) | 1994-07-15 | 2011-05-03 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US20030026782A1 (en) * | 1995-02-07 | 2003-02-06 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP0879284B1 (en) * | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DK1077722T3 (en) | 1998-05-22 | 2006-11-27 | Ottawa Health Research Inst | Methods and products for the induction of mucosa immunity |
US6977245B2 (en) | 1999-04-12 | 2005-12-20 | The United States Of America As Represented By The Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
WO2000061151A2 (en) | 1999-04-12 | 2000-10-19 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Oligodeoxynucleotide and its use to induce an immune response |
US7223398B1 (en) * | 1999-11-15 | 2007-05-29 | Dynavax Technologies Corporation | Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof |
ATE378348T1 (en) * | 2000-01-14 | 2007-11-15 | Us Health | OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE |
WO2001095935A1 (en) * | 2000-01-20 | 2001-12-20 | Ottawa Health Research Institute | Immunostimulatory nucleic acids for inducing a th2 immune response |
US20040131628A1 (en) * | 2000-03-08 | 2004-07-08 | Bratzler Robert L. | Nucleic acids for the treatment of disorders associated with microorganisms |
US20010046967A1 (en) * | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
US20020107212A1 (en) * | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US20020028784A1 (en) * | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) * | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US7129222B2 (en) * | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US20020098199A1 (en) * | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
CA2420621C (en) * | 2000-09-28 | 2011-05-24 | Chiron Corporation | Microparticle compositions and methods for the manufacture thereof |
US20030199466A1 (en) | 2001-06-21 | 2003-10-23 | Fearon Karen L. | Chimeric immunomodulatory compounds and methods of using the same - ll |
US7666674B2 (en) | 2001-07-27 | 2010-02-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo |
WO2003012061A2 (en) * | 2001-08-01 | 2003-02-13 | Coley Pharmaceutical Gmbh | Methods and compositions relating to plasmacytoid dendritic cells |
US20030133988A1 (en) * | 2001-08-07 | 2003-07-17 | Fearon Karen L. | Immunomodulatory compositions, formulations, and methods for use thereof |
WO2003020884A2 (en) | 2001-08-14 | 2003-03-13 | The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services | Method for rapid generation of mature dendritic cells |
US8466116B2 (en) | 2001-12-20 | 2013-06-18 | The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
AU2002366710A1 (en) | 2001-12-20 | 2003-07-09 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US8263091B2 (en) | 2002-09-18 | 2012-09-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides |
EP2241325B1 (en) | 2002-10-29 | 2012-02-08 | Coley Pharmaceutical Group, Inc. | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
EP1572122A4 (en) * | 2002-11-01 | 2008-04-09 | Us Gov Health & Human Serv | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
JP2006512927A (en) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5 'CPG nucleic acids and methods of use thereof |
DE60329223D1 (en) | 2002-12-23 | 2009-10-22 | Dynavax Tech Corp | OLIGONUCLEOTIDES WITH AN IMMUNE SYSTEM STIMULATING SEQUENCE AND METHOD FOR THEIR APPLICATION |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
AU2004226605A1 (en) * | 2003-04-02 | 2004-10-14 | Coley Pharmaceutical Group, Ltd. | Immunostimulatory nucleic acid oil-in-water formulations for topical application |
WO2004110483A1 (en) * | 2003-05-31 | 2004-12-23 | Yiyou Chen | Method and composition of a novel vaccine design for the prevention and treatment of sars |
US20080027006A1 (en) * | 2004-02-12 | 2008-01-31 | The Regents Of The University Of Colorado | Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity |
CA2600036A1 (en) | 2005-03-04 | 2006-09-14 | Dynavax Technologies Corporation | Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients |
SG161260A1 (en) * | 2005-04-08 | 2010-05-27 | Coley Pharm Group Inc | Methods for treating infectious disease exacerbated asthma |
WO2008057529A2 (en) * | 2006-11-06 | 2008-05-15 | Coley Pharmaceutical Group, Inc. | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp) |
WO2009140626A2 (en) | 2008-05-15 | 2009-11-19 | Dynavax Technologies Corporation | Long term disease modification using immunostimulatory oligonucleotides |
MX2011010050A (en) | 2009-03-25 | 2011-12-14 | Univ Texas | Compositions for stimulation of mammalian innate immune resistance to pathogens. |
WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4948882A (en) * | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
US5118800A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5015733A (en) * | 1983-12-20 | 1991-05-14 | California Institute Of Technology | Nucleosides possessing blocked aliphatic amino groups |
US5118802A (en) * | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
US4849513A (en) * | 1983-12-20 | 1989-07-18 | California Institute Of Technology | Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups |
US5093232A (en) * | 1985-12-11 | 1992-03-03 | Chiron Corporation | Nucleic acid probes |
US4910300A (en) * | 1985-12-11 | 1990-03-20 | Chiron Corporation | Method for making nucleic acid probes |
US5015882A (en) * | 1986-09-03 | 1991-05-14 | Texas Instruments Incorporated | Compound domino CMOS circuit |
US5124246A (en) * | 1987-10-15 | 1992-06-23 | Chiron Corporation | Nucleic acid multimers and amplified nucleic acid hybridization assays using same |
US5278302A (en) * | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
EP0468520A3 (en) | 1990-07-27 | 1992-07-01 | Mitsui Toatsu Chemicals, Inc. | Immunostimulatory remedies containing palindromic dna sequences |
US5616461A (en) * | 1992-05-14 | 1997-04-01 | Dana-Farber Cancer Institute | Assay for antiviral activity using complex of herpesvirus origin of replication and cellular protein |
US5849719A (en) | 1993-08-26 | 1998-12-15 | The Regents Of The University Of California | Method for treating allergic lung disease |
WO1995026204A1 (en) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Immune stimulation by phosphorothioate oligonucleotide analogs |
US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
PT772619E (en) | 1994-07-15 | 2006-10-31 | Univ Iowa Res Found | OLIGONUCLEOTIDOS IMUNOMODULADORES |
US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US5874089A (en) * | 1995-10-02 | 1999-02-23 | Georgetown University School Of Medicine | Protecting against canine oral papillomavirus (copy) |
EP0879284B1 (en) | 1996-01-30 | 2009-07-29 | The Regents of The University of California | Gene expression vectors which generate an antigen specific immune response and methods of using the same |
CA2268825C (en) | 1996-10-11 | 2006-04-18 | The Regents Of The University Of California | Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
JP2001513776A (en) | 1997-02-28 | 2001-09-04 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | Use of nucleic acids containing unmethylated CpG dinucleotides in the treatment of LPS-related disorders |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DK1005368T3 (en) * | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants |
EP0983289A4 (en) | 1997-05-19 | 2001-04-25 | Merck & Co Inc | Oligonucleotide adjuvant |
AU7690898A (en) | 1997-05-20 | 1998-12-11 | Ottawa Civic Hospital Loeb Research Institute | Vectors and methods for immunization or therapeutic protocols |
JP4101888B2 (en) | 1997-06-06 | 2008-06-18 | ダイナバックス テクノロジーズ コーポレイション | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
JP4663113B2 (en) | 1997-09-05 | 2011-03-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Use of immunostimulatory oligonucleotides to prevent or reduce antigen-stimulated granulocyte-mediated inflammation |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
ATE356630T1 (en) | 1998-04-03 | 2007-04-15 | Univ Iowa Res Found | METHOD AND PRODUCTS FOR STIMULATING THE IMMUNE SYSTEM USING IMMUNOTHERAPEUTIC OLIGONUCLEOTIDES AND CYTOKINE |
WO1999056755A1 (en) | 1998-05-06 | 1999-11-11 | University Of Iowa Research Foundation | Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides |
JP2002514397A (en) * | 1998-05-14 | 2002-05-21 | コーリー ファーマシューティカル ゲーエムベーハー | Methods for hematopoietic regulation using CpG oligonucleotides |
US6562798B1 (en) | 1998-06-05 | 2003-05-13 | Dynavax Technologies Corp. | Immunostimulatory oligonucleotides with modified bases and methods of use thereof |
WO2000006588A1 (en) | 1998-07-27 | 2000-02-10 | University Of Iowa Research Foundation | STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS |
EP1113818B1 (en) | 1998-09-18 | 2006-05-17 | Dynavax Technologies Corporation | METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN |
CA2344558A1 (en) | 1998-10-09 | 2000-04-20 | Dynavax Technologies Corporation | Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens |
AU762857B2 (en) * | 1999-04-20 | 2003-07-10 | Smithkline Beecham Biologicals (Sa) | Vaccine |
ATE275727T1 (en) | 1999-04-29 | 2004-09-15 | Coley Pharm Gmbh | SCREENING FOR MODULATORS OF IMMUNO-STIMULATIVE DNA FUNCTION |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
JP2003507341A (en) | 1999-08-19 | 2003-02-25 | ダイナバックス テクノロジーズ コーポレイション | Immunostimulatory sequences and methods for modulating an immune response with compositions for using the same and compositions for using the same |
CA2398756A1 (en) | 2000-01-31 | 2001-08-02 | Eyal Raz | Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen |
CA2399550A1 (en) * | 2000-02-23 | 2001-08-30 | The Regents Of The University Of California | Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation |
US7129222B2 (en) | 2000-03-10 | 2006-10-31 | Dynavax Technologies Corporation | Immunomodulatory formulations and methods for use thereof |
US7157437B2 (en) * | 2000-03-10 | 2007-01-02 | Dynavax Technologies Corporation | Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences |
US20030129251A1 (en) | 2000-03-10 | 2003-07-10 | Gary Van Nest | Biodegradable immunomodulatory formulations and methods for use thereof |
US20020098199A1 (en) * | 2000-03-10 | 2002-07-25 | Gary Van Nest | Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences |
US20020107212A1 (en) | 2000-03-10 | 2002-08-08 | Nest Gary Van | Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences |
US20020028784A1 (en) | 2000-03-10 | 2002-03-07 | Nest Gary Van | Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences |
US20010046967A1 (en) | 2000-03-10 | 2001-11-29 | Gary Van Nest | Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide |
CA2404041A1 (en) * | 2000-03-28 | 2001-10-04 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
WO2001076642A1 (en) | 2000-04-07 | 2001-10-18 | The Regents Of The University Of California | Synergistic improvements to polynucleotide vaccines |
-
2001
- 2001-03-09 US US09/802,686 patent/US20010046967A1/en not_active Abandoned
- 2001-03-12 WO PCT/US2001/007839 patent/WO2001068116A2/en active IP Right Grant
- 2001-03-12 AU AU4358701A patent/AU4358701A/en active Pending
- 2001-03-12 DE DE60142775T patent/DE60142775D1/en not_active Expired - Lifetime
- 2001-03-12 CA CA2402268A patent/CA2402268C/en not_active Expired - Fee Related
- 2001-03-12 JP JP2001566680A patent/JP2003526672A/en active Pending
- 2001-03-12 AT AT01916581T patent/ATE476983T1/en not_active IP Right Cessation
- 2001-03-12 EP EP01916581A patent/EP1261352B1/en not_active Expired - Lifetime
- 2001-03-12 AU AU2001243587A patent/AU2001243587C1/en not_active Ceased
-
2003
- 2003-04-29 US US10/426,237 patent/US20040009942A1/en not_active Abandoned
-
2009
- 2009-07-28 US US12/510,849 patent/US8226957B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU4358701A (en) | 2001-09-24 |
JP2003526672A (en) | 2003-09-09 |
EP1261352B1 (en) | 2010-08-11 |
AU2001243587C1 (en) | 2006-11-16 |
AU2001243587B2 (en) | 2005-11-24 |
US20040009942A1 (en) | 2004-01-15 |
WO2001068116A2 (en) | 2001-09-20 |
CA2402268C (en) | 2012-10-02 |
EP1261352A2 (en) | 2002-12-04 |
ATE476983T1 (en) | 2010-08-15 |
US20010046967A1 (en) | 2001-11-29 |
DE60142775D1 (en) | 2010-09-23 |
US20100035975A1 (en) | 2010-02-11 |
US8226957B2 (en) | 2012-07-24 |
WO2001068116A3 (en) | 2002-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2402268A1 (en) | Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections | |
JP2003535043A5 (en) | ||
WO2001068077A3 (en) | Immunostimulatory polynucleotide sequences for use in preventing and treating viral infections | |
JP2003526670A5 (en) | ||
JP2003526672A5 (en) | ||
WO2001068103A3 (en) | Treatment of herpes infection using immunomodulatory polynucleotide sequences | |
Ivanov et al. | Interleukin-22 reduces lung inflammation during influenza A virus infection and protects against secondary bacterial infection | |
WO2006034292A3 (en) | Antibodies against and methods for producing vaccines for respiratory syncytial virus | |
ATE250937T1 (en) | VACCINE PREPARATIONS CONTAINING CHITOSAN AND INFLUENZA ANTIGEN(S) FOR ADMINISTRATION THROUGH A MUCOSA | |
WO2003026589A3 (en) | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides | |
WO1995003056A1 (en) | Hepatitis c virus proliferation inhibitor | |
HU228687B1 (en) | Novel composition | |
BR9812232A (en) | Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic | |
WO2001089559A3 (en) | Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine | |
WO2002043660A3 (en) | Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment | |
Hancock et al. | CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV) | |
Merolla et al. | Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta. | |
ATE226829T1 (en) | PHARMACEUTICAL COMPOSITION, CONTAINING SERUM AMYLOID P COMPONENTS, FOR THE PROPHYLAXIS AND THERAPY OF VIRAL INFECTIONS AND KIT FOR THE DETECTION OF COMPLEXES BETWEEN SUCH COMPOSITIONS AND VIRAL COMPONENTS | |
Dobson‐Belaire et al. | Neisseria gonorrhoeae effectively blocks HIV‐1 replication by eliciting a potent TLR9‐dependent interferon‐α response from plasmacytoid dendritic cells | |
Prince et al. | Mechanism of antibody-mediated viral clearance in immunotherapy of respiratory syncytial virus infection of cotton rats | |
WO2005076001A3 (en) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual | |
WO2006085979A3 (en) | Soluble forms of hendra and nipah virus g glycoprotein | |
WO2004052905A3 (en) | Antiviral nucleoside derivatives | |
EA006211B1 (en) | Vaccines including as an adjuvant type 1 ifn and processes related thereto | |
Webster | Virus infections in primary immunodeficiency. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180312 |